Julia G. Butchko Sells 10,115 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock

Immunovant, Inc. (NASDAQ:IMVT) insider Julia G. Butchko sold 10,115 shares of the business’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $29.06, for a total value of $293,941.90. Following the completion of the transaction, the insider now directly owns 451,627 shares in the company, valued at $13,124,280.62. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Immunovant Stock Performance

NASDAQ:IMVT opened at $28.22 on Friday. Immunovant, Inc. has a 52 week low of $15.08 and a 52 week high of $45.58. The firm has a 50-day moving average price of $33.00 and a two-hundred day moving average price of $36.06. The firm has a market cap of $4.10 billion, a price-to-earnings ratio of -15.34 and a beta of 0.65.

Immunovant (NASDAQ:IMVT) last issued its quarterly earnings results on Monday, February 12th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. As a group, sell-side analysts forecast that Immunovant, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Wolfe Research initiated coverage on Immunovant in a research note on Thursday, February 15th. They issued an “outperform” rating and a $55.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunovant in a research report on Friday, January 12th. JPMorgan Chase & Co. initiated coverage on shares of Immunovant in a report on Tuesday, February 20th. They issued an “overweight” rating and a $51.00 price target for the company. Oppenheimer started coverage on shares of Immunovant in a report on Thursday, March 28th. They set an “outperform” rating and a $50.00 price objective on the stock. Finally, Truist Financial reaffirmed a “buy” rating and issued a $48.00 target price on shares of Immunovant in a research report on Monday, March 25th. Seventeen research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $48.00.

Institutional Investors Weigh In On Immunovant

Large investors have recently made changes to their positions in the business. WCM Investment Management LLC purchased a new stake in Immunovant during the fourth quarter worth about $4,548,000. AWM Investment Company Inc. bought a new stake in shares of Immunovant in the 3rd quarter worth approximately $1,920,000. Wellington Management Group LLP purchased a new position in Immunovant in the third quarter valued at approximately $6,473,000. Citigroup Inc. lifted its stake in Immunovant by 43.3% in the third quarter. Citigroup Inc. now owns 126,316 shares of the company’s stock valued at $4,849,000 after purchasing an additional 38,179 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Immunovant by 14.0% in the third quarter. Vanguard Group Inc. now owns 6,233,146 shares of the company’s stock worth $239,290,000 after buying an additional 764,530 shares during the last quarter. 47.08% of the stock is owned by hedge funds and other institutional investors.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.